Soligenix Q1 2023 Earnings Report

Soligenix EPS Results

• Actual EPS: -$5.76
• Consensus EPS: -$20.00
• Beat/Miss: Beat by +$14.24
• One Year Ago EPS: N/A

Soligenix Revenue Results

• Actual Revenue: $0.26 million
• Expected Revenue: $0.20 million
• Beat/Miss: Beat by +$60.00 thousand
• YoY Revenue Growth: N/A

Soligenix Announcement Details

• Quarter: Q1 2023
• Date: 5/15/2023
• Time: N/A

Soligenix (NASDAQ:SNGX), a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.